Department of Pediatric Hematology-Oncology, APHM, Timone Hospital, Aix-Marseille University, Marseille, France.
Department of Pediatric Hematology-Oncology, Montpellier University Hospital, Montpellier, France.
Biol Blood Marrow Transplant. 2019 Apr;25(4):734-742. doi: 10.1016/j.bbmt.2018.10.016. Epub 2018 Oct 29.
We previously reported in a French prospective randomized study that transplantation of 2 unrelated cord blood (UCB) units instead of 1 unit does not decrease the risk of transplantation failure but may enhance alloreactivity. Here we evaluated the influence of pretransplantation minimal residual disease (MRD) on leukemia relapse and survival after single- versus double-UCB transplantation (UCBT). Among 137 children and young adults who underwent UCBT in this randomized study, 115 had available data on MRD assessment done immediately before initiation of the pretransplantation conditioning regimen. MRD was considered positive at a level of ≥10, which was the case of 43 out of 115 patients. Overall, the mean 3-year survival probability was 69.1 ± 4.4%, and it was not significantly influenced by the MRD level: 70.7 ± 5.4% in MRD-negative (<10) patients (n = 72), 71.1 ± 9.4% in MRD-positive patients with 10 ≤ MRD <10 (n = 26) and 58.8 ± 11.9% in MRD-positive patients with ≥10 (n = 17). In the MRD-positive group, the mean risk of relapse was significantly lower in the double-UCBT arm compared with the single-UCBT arm (10.5 ± 7.2% versus 41.7 ± 10.4%; P = .025) leading to a higher mean 3-year survival rate (82.6 ± 9.3% versus 53.6 ± 10.3%; P = .031). This difference was observed only in patients who had not received antithymocyte globulin during their conditioning regimen. In the MRD-negative group, there was no differencebetween the single- and the double-UCBT arms. We conclude that even in cases of positive pretransplantation MRD, UCBT in children and young adults with acute leukemia yields a high cure rate, and that a double-unit strategy may enhance the graft-versus-leukemia effect and survival in these patients.
我们之前在一项法国前瞻性随机研究中报告,与移植 1 个无关脐带血 (UCB) 单位相比,移植 2 个 UCB 单位不会降低移植失败的风险,但可能增强同种异体反应性。在这里,我们评估了移植前微小残留病 (MRD) 对单 UCB 与双 UCB 移植 (UCBT) 后白血病复发和生存的影响。在这项随机研究中,137 名儿童和年轻成年人接受了 UCBT,其中 115 名患者有移植前预处理方案开始前进行的 MRD 评估的可用数据。MRD 水平被认为是阳性,水平≥10,其中 43 例患者属于这种情况。总体而言,3 年平均生存率为 69.1 ± 4.4%,并且不受 MRD 水平的显著影响:MRD 阴性(<10)患者(n = 72)的 70.7 ± 5.4%,MRD 阳性患者中 10 ≤ MRD <10 的患者(n = 26)为 71.1 ± 9.4%,MRD 阳性患者中≥10 的患者为 58.8 ± 11.9%(n = 17)。在 MRD 阳性组中,与单 UCBT 相比,双 UCBT 组的复发平均风险明显降低(10.5 ± 7.2%对 41.7 ± 10.4%;P =.025),导致 3 年平均生存率更高(82.6 ± 9.3%对 53.6 ± 10.3%;P =.031)。这种差异仅在预处理方案中未接受抗胸腺细胞球蛋白的患者中观察到。在 MRD 阴性组中,单 UCBT 与双 UCBT 组之间无差异。我们的结论是,即使在移植前 MRD 阳性的情况下,儿童和年轻成年人急性白血病的 UCBT 也能获得很高的治愈率,并且双单位策略可能会增强这些患者的移植物抗白血病效应和生存。